Latest news

• Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

  roll-out stage for two new products,   Tegsedi (inotersen) for hereditary transthyretin-mediated amyloidosis and  Waylivra (volanesorsen) for familial chylomicronemia syndrome (FCS).

• Akcea gets first OK for Waylivra in rare triglyceride disorder

  EU becomes the first market for the new drug. Akcea has been granted a conditional approval for Waylivra, its antisense drug for rare inherited disorder familial chylomicronemia syndrome (FCS), in Europe. ... Waylivra last August despite a 12 to 8 vote

• Akcea steals march on Alnylam with NICE approval

  NICE’s ruling adds to the good news for Akcea, which in March gained a CHMP recommendation for Waylivra (volanesorsen), which would be its second drug to reach market.

• CHMP backs Lynparza in breast cancer, Dupixent in asthma

  Akcea's FDA-rejected Waylivra also recommended. The EMA’s main advisory committee for medicines backed new indications for AstraZeneca and Merck &Co/MSD’s Lynparza and Sanofi’s Dupixent that ... The committee recommended a conditional marketing

• Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

  FDA rejects Waylivra, Roivant group continues gene therapy drive, UK biotech gains £637k. ... The regulator's Division of Metabolism and Endocrinology Products issued the response to Waylivra (volanesorsen),   Akcea's treatment for the ultra-rare and